TaiMed Biologics Inc. (TPEX: 4147)
Health Care · Biotechnology · TW
NT$61.20
-0.33% today · -15.4% 1Y
TaiMed Biologics Inc. (TPEX: 4147) operates in the Biotechnology industry within the Health Care sector. The company is valued at $522.91M and employs 799 people.
Over the last twelve months the share price has lost 15.4%, trading between 47.00 and 76.80.
Tweenvest scores TaiMed Biologics Inc. across four factors: quality 78/100, value 53/100. Its strongest factor is quality.
4147 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $522.91M
- Revenue (TTM)
- $19.47M
- P/E
- —
- EPS
- -0.51
- Dividend yield
- —
- Beta (5Y)
- -0.07
- 52-week high
- NT$76.80
- 52-week low
- NT$47.00
- Avg volume (3M)
- —
- Shares outstanding
- 273.20M
- Employees
- 799
- Next earnings
- —
About TaiMed Biologics Inc.
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates for cancer treatment. In addition, the company offers contract development and manufacturing services. It has a research and development agreement with Genentech and Biogen Inc. for Trogarzo TMB-355; and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei, Taiwan.
- ISIN
- TW0004147004
- Founded
- 2007
- Listed since
- Jun 20, 2012
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Bright Minds Biosciences Inc.CNSX: DRUG | $533.01M | CA$77.10 | +9.22% |
| Puma Biotechnology, Inc.NasdaqGS: PBYI | $531.17M | $10.29 | 0.00% |
| Monopar Therapeutics Inc.NasdaqCM: MNPR | $529.99M | $77.05 | -2.42% |
| CytomX Therapeutics, Inc.NasdaqGS: CTMX | $527.32M | $2.42 | -5.84% |
| Qingdao Vland Biotech INC.SHSE: 603739 | $522.82M | CN¥13.84 | -1.42% |
| Wuhan Hiteck Biological Pharma Co.,LtdSZSE: 300683 | $516.50M | CN¥26.43 | +3.48% |
| REGENXBIO Inc.NasdaqGS: RGNX | $512.92M | $7.77 | -3.72% |
| Lifecome Biochemistry Co.,Ltd.SZSE: 002868 | $512.79M | CN¥22.10 | -0.90% |
Figures last refreshed Oct 11, 2026.